scholarly journals Longitudinal multiparametric characterization of platelet dysfunction in COVID-19: Effects of disease severity, anticoagulation therapy and inflammatory status

Author(s):  
Alexey A. Martyanov ◽  
Anna E. Boldova ◽  
Maria G. Stepanyan ◽  
Olga I. An ◽  
Alexander S. Gur'ev ◽  
...  
2017 ◽  
Vol 112 (3) ◽  
pp. 457a-458a
Author(s):  
Jared Houghtaling ◽  
Michael Mayer

2020 ◽  
Author(s):  
Mansoor Kodori ◽  
Zohreh Ghalavand ◽  
Abbas Yadegar ◽  
Gita Eslami ◽  
Masoumeh Azimirad ◽  
...  

Abstract Background: Clostridioides difficile is the main cause of healthcare-associated diarrhea worldwide. It is proposed that certain C. difficile toxinotypes with distinct pathogenicity locus (PaLoc) variants are associated with disease severity and outcomes. Additionally, few studies have described the common C. difficile toxinotypes, and also little is known about the tcdC variants in Iranian isolates. We characterized the toxinotypes and the tcdC genotypes from a collection of Iranian clinical C. difficile tcdA+B+ isolates with known ribotypes (RTs).Methods: Fifty C. difficile isolates with known RTs and carrying the tcdA and tcdB toxin genes were analyzed. Toxinotyping was carried out based on a PCR-RFLP analysis of a 19.6 kb region encompassing the PaLoc. Genetic diversity of the tcdC gene was determined by the sequencing of the gene.Results: Of the 50 C. difficile isolates investigated, five distinct toxinotypes were recognized. Toxinotypes 0 (33/50, 66%) and V (11/50, 22%) were the most frequently found. C. difficile isolates of the toxinotype 0 mostly belonged to RT 001 (12/33, 36.4%), whereas toxinotype V consisted of RT 126 (9/11, 81.8%). The tcdC sequencing showed six variants (35/50, 70%); tcdC-sc3 (24%), tcdC-A (22%), tcdC-sc9 (18%), tcdC-B (2%), tcdC-sc14 (2%), and tcdC-sc15 (2%). The remaining isolates were wild-types (15/50, 30%) in the tcdC gene.Conclusions: The present study demonstrates that the majority of clinical tcdA+B+ isolates of C. difficile frequently harbor tcdC genetic variants. We also found that the RT 001/ toxinotype 0 and the RT 126/ toxinotype V are the most common types among Iranian isolates. Further studies are needed to investigate the putative association of various tcdC genotypes with CDI severity and its recurrence.


2018 ◽  
Author(s):  
CARMEN DE MARCO ◽  
ANTONELLA BOSELLI ◽  
ANDREA D’ANNA ◽  
GIOVANNI PERILLO ◽  
ALESSIA SANNINO ◽  
...  

2015 ◽  
Vol 101 (1) ◽  
pp. e1.47-e1
Author(s):  
Matthias Gorenflo ◽  
David Pittrow ◽  
Dörte Huscher ◽  
Victoria Ziesenitz ◽  
Joseph Pattathu ◽  
...  

BackgroundPulmonary hypertension (PH/PAH) can have many possible causes in childhood. The aim of the COMPERA registry is the characterization of patients of all ages with PH/PAH and their treatment patterns.MethodsSince June 2013, paediatric patients can be included in the COMPERA registry (ClinTrials.gov: NCT01347216) which has originally been established for adult patients with pulmonary hypertension in 2007.ResultsUntil 2015, 78 patients <18 years (47 Pat <6 years) with pulmonary hypertension were enrolled, of whom 65.4% had PAH due to congenital heart disease (PAH-CHD), 25.6% had idiopathic PAH (iPAH), 3 had persistent PH of the newborn, 2 had PH associated with interstitial lung disease, and two had other PH. The patients were 6.1±6.0 years old, 52.6% girls; NYHA functional class I/II in 55.0%, and III in 42.3%. Mean disease duration after diagnosis was 37.7±55.8 months. Right heart catheterization data were available for 82.1% of the patients. Mean pulmonary artery pressure was 42.8±19.4 mmHg, right atrial pressure was 8.0±8.8 mmHg, cardiac index was 3.6±1.2 l/min/m2. Monotherapy was received by 65.4% of the patients whereas 33.4% of the patients had combination therapy. Phosphodiesterase-5 inhibitors (PDE5I) were administered to 76.9% of the patients, 35.9% of the patients received endothelin receptor antagonists and 3.8% received prostacyclins. About 24% of patients received anticoagulation therapy.ConclusionThe most common form of PH in this study cohort is PAH-CHD, followed by iPAH. Treatment options for children primarily comprise PDE5I. Only a small number of paediatric patients receive anticoagulation therapy.


Gene ◽  
2018 ◽  
Vol 660 ◽  
pp. 128-135 ◽  
Author(s):  
Hanaa H. Gaballah ◽  
Rasha A. Gaber ◽  
Ragia S. Sharshar ◽  
Samah A. Elshweikh

2017 ◽  
Vol 152 (5) ◽  
pp. S990
Author(s):  
Christine Olbjørn ◽  
Milada C. Smastuen ◽  
Christina Casen ◽  
Torbjørn Lindahl ◽  
Britt Nakstad ◽  
...  

2021 ◽  
Author(s):  
Flávio Moura Rezende Filho ◽  
Neringa Jurkute ◽  
João Brainer Clares Andrade ◽  
Bruna Ferraço Marianelli ◽  
Juliana M. Ferraz Sallum ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document